Dabrafenib plus trametinib vs encorafenib plus binimetinib in BRAF-mutant metastatic melanoma: a real-world propensity score–matched survival analysis

Journal:
Journal of the National Cancer Institute
Published:
Affiliations:
4
Authors:
13
Institutions Authors Share
National Center for Cancer Immune Therapy (CCITdk), Denmark
6.000000
0.46
Aarhus University Hospital, Denmark
3.000000
0.23
Odense University Hospital (OUH), Denmark
3.000000
0.23
Aalborg University Hospital, Denmark
1.000000
0.08